All Articles

MSG Sports posts record profits fueled by a Knicks NBA title, but the real story is the strategic gamble to split its empire, creating long-term risks.

NeuPath Health's Q2 results show headline declines, but a deeper look reveals strong organic growth from record patient visits and strategic expansion.

As Indonesia Energy Corp drills its K-29 well, we explore the strategy behind the spin. Is this about barrels of oil or building investor confidence?

Abeona Therapeutics celebrates rising sales for its life-changing RDEB therapy, ZEVASKYN. But behind the numbers lies a story of manufacturing hurdles and mounting debt.

A Kansas health plan reports near-perfect member satisfaction. But what do these numbers truly reveal about the future of long-term care and the push for data-driven dignity?

Q2 data reveals a stark divergence: private markets show steady, earnings-driven growth while public markets chase AI hype. But beneath the surface, a new era of selectivity emerges.

PO Wealth Sharing Group claims 200,000 users and a global footprint. But beneath the surface of this fintech success story lies a troubling pattern.

The FDA is betting on AI to manage chronic illness. Cadence's new pilot for its hypertension software could rewrite the rules for digital health regulation.

Facing a 'going concern' warning, Pulmatrix abandons its drug pipeline for a reverse merger, betting its survival on the high-risk field of longevity science.

A new partnership between Flip Electronics and Vishay confronts the growing crisis of component obsolescence, promising a secure, authorized channel for legacy parts.

ImpactFactory.ai launches a platform integrating 25+ AI engines to automate marketing, promising to democratize advertising. But what does this mean for the human creative?

Rigel's VEPPANU is the first FDA-approved PROTAC, a new class of drug that destroys disease proteins. This is the story behind the science and the numbers.

With a giant copper resource, Minsud Resources uses a clever partnership with South32 to fund a 10,500m drill program while preserving capital.

A Washington nonprofit reports a stunning 6% recidivism rate, far below national averages. We dissect the model combining aerospace manufacturing with social reform.

FlightHub's new AI assistant, PAX, aims to find hidden travel deals. But as it scans for bargains, the company must also navigate a history of turbulence.

Curis secures a crucial, albeit small, $5.6M funding lifeline. Will it be enough to push its promising cancer drug through trials before the clock runs out?

LightInTheBox secures $5.49M for an AI overhaul, with its CEO personally investing $1.09M. Is this the catalyst needed to thrive in a crowded market?

XbotGo's landmark deal with Best Buy isn't just a retail win; it's a signal that AI is finally becoming the ultimate tool for the modern family.

Lurie Children's new facility is more than a pharmacy; it's a look into a new system where hospitals integrate business and care to survive and thrive.

AM Best's top-tier rating affirms National Life Group's market strength, but a deeper look reveals a strategy balancing aggressive growth with complex challenges.